Date: 2013-06-26
Type of information: Collaboration agreement
Compound: early research data related to drug design
Company: AstraZeneca (UK) Roche (Switzerland)
Therapeutic area:
Type agreement: collaboration
R&D
Action mechanism:
Disease:
Details: * On June 26, 2013, Roche and AstraZeneca have announced a new collaboration to share a specific type of early research data related to drug design, which could further accelerate the discovery of high quality compounds with an increased chance of clinical success. Using a dedicated technology (Matched Molecular Pair Analysis, MMPA) modifications will be identified, which companies can apply to their compound structures in order to improve their metabolism, pharmacokinetics or safety, without divulging confidential information about their chemical structures. This gives both companies the opportunity to efficiently reapply useful medicinal chemistry know-how embedded in their combined databases of experimental results, in order to identify potential new drug candidates using fewer rounds of design, synthesis and testing.
Both Roche and AstraZeneca will make their selected databases available for this type of joint analysis and are committed to making the data generated available to the broader research community, including research foundations, charities and academia.The data-sharing will be managed through the intermediary company, MedChemica, which has expertise in the key technology of MMPA. The consortium is open to other large companies to add their knowledge thereby gaining access to and enhancing this resource. More data added to this system will raise the quality and specificity of drug design rules.
Financial terms:
Latest news:
